Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ensartinib + anlotinib
- Development stage
- Unknown
- Lead developer
- Betta Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Ensartinib + anlotinib is a combination therapy being investigated for the treatment of advanced ALK-positive non-small cell lung cancer (NSCLC), particularly in patients who have developed resistance to prior ALK tyrosine kinase inhibitors (TKIs) such as lorlatinib. Ensartinib is a potent, second-generation ALK TKI that selectively inhibits the ALK receptor tyrosine kinase and its oncogenic fusion proteins. Anlotinib is a multi-target tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR1, VEGFR2, VEGFR3), fibroblast growth factor receptors (FGFR1-4), platelet-derived growth factor receptors (PDGFRα, PDGFRβ), and c-Kit. By combining these two agents, the therapy aims to overcome resistance mechanisms by simultaneously inhibiting ALK signaling and tumor angiogenesis/proliferation pathways. This combination is currently being evaluated in exploratory clinical analyses to determine its efficacy and safety profile in heavily pre-treated patient populations.
- Brand names
- BemenaFukanghua
- Other names
- ensartinib + arotinib
02
Targets
ALK (Anaplastic lymphoma kinase receptor tyrosine kinase)NTRK3 (Tropomyosin receptor kinase C)NTRK1 (Tropomyosin-related receptor kinase A)MET (Mesenchymal-epithelial transition factor receptor)PDGFRB (Platelet-derived growth factor receptor beta)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR4 (Vascular endothelial growth factor Receptor-3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)ROS1 (Proto-oncogene tyrosine-protein kinase ROS)FGFR1 (Fibroblast growth factor receptor 1)RET (Rearranged during transfection receptor tyrosine kinase)EPHA2 (Ephrin type-A receptor 2)
Beyond the preview
Go deeper on ensartinib + anlotinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ensartinib + anlotinib.